MARKET COMPOSITE
Market TodayThemes and Stocks SummaryThematic Stock SearchDaily Refresh Schedule
STXS - Stereotaxis Inc
$7.02
0.11(1.59%)4:53:48 PM 3/5/2021
Stereotaxis Inc. is an American publicly traded corporation based in St. Louis, MO that makes robotic products to improve the clinical outcomes of electrophysiology studies. The most notable of Stereotaxis’ products is the NIOBE® ES Remote Magnetic Navigation System. With first iterations of the RMN system originally designed for applications within the brain, its current usage is guiding magnetic catheters during electrophysiology studies and catheter ablation procedures to treat arrhythmias within in the heart. The technology has been approved by regulatory agencies in the United States, European Union and other countries around the world. Systems operate within cardiac catheter labs in hospitals and have been utilized in over 100,000 procedures worldwide as of 2017.
Stock Chart

Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from 

Finra

Moving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.

Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.

Summary:

  • MACD is crossing MACD signal line at 0.1. MACD crossing signal line is bullish signal.
Stock Statistics
MarketCap509.2M
PE Ratio-62.0
PEG Ratio
P/B14.9
P/S (ttm)19.4
Earning Growth (QoQ)
Revenue Growth (QoQ)
Short %3%
Held by Institutions %55%
1 Day Vol Adjusted Return-0.9
1 Month Vol Adjusted Return5.3
3 Month Vol Adjusted Return9.9
6 Month Vol Adjusted Return17.5
20 Days SMA Price ZScore0.9
50 Days SMA Price ZScore1.8
12 -26 Days PPO10.1
1 Month Average Short Volume Ratio31.1
1 Day Volume Change ZScore-0.1
1 Month Daily Vol8.5
Related Topics
Peers

Stock news

    03/2/2021STXS
    Stereotaxis Inc. (STXS) Moves 13.6% Higher: Will This Strength Last?

    Stereotaxis Inc. (STXS) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

    02/26/2021STXS
    Stereotaxis (STXS) Q4 2020 Earnings Call Transcript

    STXS earnings call for the period ending December 31, 2020.

    02/25/2021STXS
    Stereotaxis Reports 2020 Full Year Financial Results

    ST. LOUIS, Feb. 25, 2021 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today reported financial results for the fourth quarter and full year ended December 31, 2020. “2020 was a year of significant progress despite a challenging macro environment,” said David Fischel, Chairman and CEO. “The highlight of the year was receipt of FDA clearance for the Genesis RMN System and successful installations of the...

    02/25/2021STXS
    Stereotaxis, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / February 25, 2021 / Stereotaxis, Inc. (NYSE:STXS) will be discussing their earnings results in their 2020 Fourth Quarter Earnings call to be held on February 25, 2021 at 10:00 AM Eastern Time.

    02/24/2021STXS
    Stereotaxis Announces Long-Term CEO Performance Stock Award

    ST. LOUIS, Feb. 24, 2021 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced a 10-year CEO performance stock award for David Fischel with vesting entirely contingent upon the company achieving billion-dollar market capitalization milestones. David Fischel has served as unpaid CEO of Stereotaxis since February 2017. Over his four-year tenure he has led the revitalization of Stereotaxis’ commer...

    02/11/2021STXS
    Stereotaxis to Present at Upcoming Investor Conferences

    ST. LOUIS, Feb. 11, 2021 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced that David Fischel, Chairman and CEO, will present at two investor conferences in the first quarter 2021. BTIG Virtual MedTech, Digital Health, Life Science and Diagnostic Tools Conference Mr. Fischel will present an overview of Stereotaxis business on Wednesday, February 17th, 2021, at 1:00 pm EST and will be availa...

    02/4/2021STXS
    Stereotaxis to Report Fourth Quarter and Full Year 2020 Financial Results on February 25, 2021

    ST. LOUIS, Feb. 04, 2021 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced that it will release financial results for its 2020 fourth quarter and full year ended December 31, 2020 on Thursday, February 25, 2021 before the open of the U.S. financial markets. The Company will host a conference call and webcast at 10 a.m. EST that day to discuss the Company’s results and corporate developments...